Columnist Shawna Barnes was on the hunt for a clue to her MG symptoms when a late-night search on the internet brought her to huperzine A.| Myasthenia Gravis News
Circulating inflammatory molecules called cytokines may be associated with a risk for developing myasthenia gravis, a recent study suggests.| Myasthenia Gravis News
Columnist Shawna Barnes delves into pyridostigmine bromide's history and its crucial role as an MG treatment.| Myasthenia Gravis News
Columnist Shawna Barnes is ready for some emotional separation from myasthenia gravis, so she's delivering it a breakup letter.| Myasthenia Gravis News
Gefurulimab outperformed a placebo in easing gMG symptoms in a clinical trial involving over 250 patients positive for anti-AChR antibodies.| Myasthenia Gravis News
The anti-inflammatory therapy telitacicept for myasthenia gravis was granted orphan drug status in the EU by the European Medicines Agency.| Myasthenia Gravis News
Zilbrysq was found safe and effective in a clinical trial for generalized myasthenia gravis patients who switched from other C5 inhibitors.| Myasthenia Gravis News
Vor Bio signed an exclusive license agreement to develop and market Remegen’s telitacicept for MG outside China, Hong Kong, Macau, and Taiwan.| Myasthenia Gravis News
Thymectomy led to a long-term reduction in the levels of immune T-cells and to temporary changes in cytokine levels in MG patients.| Myasthenia Gravis News
The FDA has approved once-daily zilucoplan as Zilbrysq for adults with generalized MG who are positive for antibodies targeting AChR.| Myasthenia Gravis News
Study data show long-term treatment with Zilbrysq led to sustained reductions in disease severity in generalized myasthenia gravis patients.| Myasthenia Gravis News
Esteban holds a Master of Science in Immunology from the Instituto Politécnico Nacional in Mexico, focused on inflammation and metabolism. With five years of experience as a Medical Science Liaison, he has worked directly with physicians across a wide range of specialties, covering topics...| Myasthenia Gravis News
Treatment with nipocalimab in gMG patients led to significant reductions in disease severity, per top-line data from a pivotal Phase 3 trial.| Myasthenia Gravis News
More than half of MG patients in a study had fatigue and its severity correlated with disease worsening, crises, and delays in diagnosis.| Myasthenia Gravis News
A 64-year-old woman with dropped head syndrome was found to have a form of MG with antibodies against MuSK, and weak spine muscles.| Myasthenia Gravis News
Rituximab isn't officially approved for MG, but is used off-label when standard treatments fail, such as patients with anti-MuSK antibodies.| Myasthenia Gravis News
Columnist Shawna Barnes shares the hard-earned wisdom that would've helped her navigate life with myasthenia gravis after her diagnosis.| Myasthenia Gravis News
Lindsey Shapiro is a science writer for Myasthenia Gravis News with a PhD in neuroscience. She covers the latest news and information on a variety of myasthenia gravis topics.| Myasthenia Gravis News
An open-label, multicenter Phase 2 clinical trial will test KYV-101 in people with refractory MG and positive for self-reactive antibodies.| Myasthenia Gravis News
Columnist Shawna Barnes, who has seronegative myasthenia gravis, is happy with her treatments and sees no reason now to change them.| Myasthenia Gravis News
Joana Carvalho is a managing science editor for BioNews with a PhD in biomedical sciences. She edits and fact-checks articles on a variety of rare and chronic disease topics.| Myasthenia Gravis News
Marisa Wexler is a senior science writer for Myasthenia Gravis News with an MS in cellular and molecular pathology. She covers the latest news and information on a variety of myasthenia gravis topics.| Myasthenia Gravis News
Vanda Pinto is a science writer for Myasthenia Gravis News with a PhD in biomedicine. She covers the latest news and information on a variety of myasthenia gravis topics.| Myasthenia Gravis News
Steve Bryson is a science writer for Myasthenia Gravis News with a PhD in biochemistry. He covers the latest news and information on a variety of myasthenia gravis topics.| Myasthenia Gravis News
Margarida Maia is a science writer for Myasthenia Gravis News with a PhD in biomedical sciences. She covers the latest news and information on a variety of myasthenia gravis topics.| Myasthenia Gravis News
Andrea Lobo is a Science writer at BioNews. She holds a Biology degree and a PhD in Cell Biology/Neurosciences from the University of Coimbra-Portugal, where she studied stroke biology. She was a postdoctoral and senior researcher at the Institute for Research and Innovation in Health in Porto...| Myasthenia Gravis News
Generalized myasthenia gravis patients with mild muscle weakness saw more relief after surgery than those with moderate or severe weakness.| Myasthenia Gravis News
Category archive page for News.| Myasthenia Gravis News
Remegen enrolled the first U.S. patient in a Phase 3 trial testing the safety and efficacy of telitacicept for generalized myasthenia gravis.| Myasthenia Gravis News
The anti-malaria drug dihydroartemisinin, known as DHA, showed promise for treating myasthenia gravis in a rat model of MG, per a new study.| Myasthenia Gravis News
Soliris effectively eased symptoms and reduced the need for other medications in adults with MG in a clinical practice setting, data show.| Myasthenia Gravis News
People with gMG with difficulty getting diagnosed or hard-to-manage disease symptoms accrue higher healthcare-related costs, per a study.| Myasthenia Gravis News
Having a thymectomy was found to significantly ease neurological symptoms in MG patients older than 65 with a thymus tumor, per a new study.| Myasthenia Gravis News
Scientists have identified a set of inflammatory molecules that could be useful as biomarkers to aid in MG diagnosis and classification.| Myasthenia Gravis News